Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
February 24, 2023
Three-Dimensional Humanized Model of the Periodontal Gingival Pocket to Study Oral Microbiome
Miryam Adelfio, Zaira Martin-Moldes, Joshua Erndt-Marino, et al.
Biomaterials
|
June 20, 2018
Multi-channel silk sponge mimicking bone marrow vascular niche for platelet production
Lorenzo Tozzi, Pierre-Alexandre Laurent, Christian A Di Buduo, et al.
Experimental Hematology
|
November 3, 2007
MicroRNA expression profile in granulocytes from primary myelofibrosis patients
Paola Guglielmelli, Lorenzo Tozzi, Alessandro Pancrazzi, et al.
Haematologica
|
January 2, 2008
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia
Elisabetta Antonioli, Paola Guglielmelli, Giada Poli, et al.
Haematologica
|
April 27, 2010
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia
Elisabetta Antonioli, Alessandra Carobbio, Lisa Pieri, et al.
Journal of Biomedical Materials Research. Part B, Applied Biomaterials
|
April 27, 2018
Biodegradable silk catheters for the delivery of therapeutics across anatomical repair sites
Joseph E Brown, Lorenzo Tozzi, Benjamin Schilling, et al.
Blood
|
January 11, 2015
Programmable 3D silk bone marrow niche for platelet generation ex vivo and modeling of megakaryopoiesis pathologies
Christian A Di Buduo, Lindsay S Wray, Lorenzo Tozzi, et al.
Cell Death & Disease
|
November 10, 2021
Genetic inhibition of RIPK3 ameliorates functional outcome in controlled cortical impact independent of necroptosis
Limin Wu, Joon Yong Chung, Tian Cao, et al.
Blood
|
November 7, 2012
Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation
Vittorio Rosti, Laura Villani, Roberta Riboni, et al.
Blood
|
July 5, 2011
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis
Paola Guglielmelli, Giovanni Barosi, Alessandro Rambaldi, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
February 24, 2023
Three-Dimensional Humanized Model of the Periodontal Gingival Pocket to Study Oral Microbiome
Miryam Adelfio, Zaira Martin-Moldes, Joshua Erndt-Marino, et al.
Biomaterials
|
June 20, 2018
Multi-channel silk sponge mimicking bone marrow vascular niche for platelet production
Lorenzo Tozzi, Pierre-Alexandre Laurent, Christian A Di Buduo, et al.
Experimental Hematology
|
November 3, 2007
MicroRNA expression profile in granulocytes from primary myelofibrosis patients
Paola Guglielmelli, Lorenzo Tozzi, Alessandro Pancrazzi, et al.
Haematologica
|
January 2, 2008
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia
Elisabetta Antonioli, Paola Guglielmelli, Giada Poli, et al.
Haematologica
|
April 27, 2010
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia
Elisabetta Antonioli, Alessandra Carobbio, Lisa Pieri, et al.
Journal of Biomedical Materials Research. Part B, Applied Biomaterials
|
April 27, 2018
Biodegradable silk catheters for the delivery of therapeutics across anatomical repair sites
Joseph E Brown, Lorenzo Tozzi, Benjamin Schilling, et al.
Blood
|
January 11, 2015
Programmable 3D silk bone marrow niche for platelet generation ex vivo and modeling of megakaryopoiesis pathologies
Christian A Di Buduo, Lindsay S Wray, Lorenzo Tozzi, et al.
Cell Death & Disease
|
November 10, 2021
Genetic inhibition of RIPK3 ameliorates functional outcome in controlled cortical impact independent of necroptosis
Limin Wu, Joon Yong Chung, Tian Cao, et al.
Blood
|
November 7, 2012
Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation
Vittorio Rosti, Laura Villani, Roberta Riboni, et al.
Blood
|
July 5, 2011
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis
Paola Guglielmelli, Giovanni Barosi, Alessandro Rambaldi, et al.
Page
of 3